Performance of a 62Zn/62Cu microgenerator in kit-based synthesis and delivery of [62Cu]Cu–ETS for PET perfusion imaging by Ng, Yen et al.
Performance of a 62Zn/62Cu Microgenerator in Kit-Based 
Synthesis and Delivery of [62Cu]Cu-ETS for PET Perfusion 
Imaging
Yen Ng1, Jeffrey L. Lacy2, James W. Fletcher1, and Mark A. Green1
1Indiana University School of Medicine, Indianapolis, IN, USA
2Proportional Technologies, Inc (PTI)., Houston, TX, USA
Abstract
The performance of a commercially produced 62Zn/62Cu microgenerator system, and an 
associated kit-based radiopharmaceutical synthesis method, was evaluated for clinical site 
production of [62Cu]Cu-ETS (ethylglyoxal bis(thiosemicarbazonato)copper(II)), an investigational 
agent for PET perfusion imaging. Using 37 generators, containing 1.84 ± 0.23 GBq 62Zn at 9:00 
AM on the day of clinical use, a total of 45 patient doses of [62Cu]Cu-ETS (672 ± 172 MBq) were 
delivered without difficulty. 62Cu elution yields were high (approximately 90%), accompanied by 
extremely low 62Zn breakthrough (<0.001%). Radiopharmaceutical preparation, from the start-of-
elution to time-of-injection, consumed less than five minutes. The 62Zn/62Cu microgenerator was 
a dependable source of short-lived positron-emitting 62Cu, and the kit-based synthesis proved to 
be rapid, robust, and highly reliable for “on-demand” delivery of [62Cu]Cu-ETS for PET perfusion 
imaging.
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1. Introduction
Copper-62 (β+ 98%, t1/2: 9.7 min.) is formed by the decay of cyclotron-produced 62Zn (t1/2: 
9.2 hours) and offers attractive nuclear and chemical properties for many PET applications. 
Its nearly 10-minute half-life is compatible with relatively long image acquisition periods 
for good counting statistics, and yet remains short enough to permit repeat scanning within a 
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single imaging session (e.g., performance of stress/rest perfusion studies, or combination 
studies with other radiopharmaceuticals such as 18F-FDG).
A number of designs have been reported for 62Zn/62Cu generator systems that deliver 62Cu 
in forms suitable for radiopharmaceutical synthesis (Robinson, Zielinski, and Lee 1980; 
Fujibayashi, et al., 1989; Green, et al., 1990; Zweit, et al., 1992; Haynes, et al., 2000). One 
widely used approach to 62Zn/62Cu generator construction has been reliance on a design 
reported by Robinson, et al., (1980) in which selective 62Zn(II) retention is provided by an 
anion exchange resin. For maximum recovery of 62Cu from the generator column, an acidic 
elution solvent containing 2.0 molar chloride ion is normally used. Under these conditions, 
the anion exchange resin avidly adsorbs the 62Zn(II) as [ZnCl3(H2O)]1−, while the 62Cu2+ 
ions are more loosely bound as CuCl2(H2O)2 and can be selectively eluted from the column 
on-demand (Kraus and Moore, 1952).
62Cu-labeled ethylglyoxal bis(thiosemicarbazone) ([62Cu]Cu-ETS) (Figure 1), a lipophilic 
agent, has been identified as having favorable characteristics for in vivo organ perfusion 
imaging with PET (John and Green, 1989; Green, et al., 2007, 2009; Lacy, et al., 2007, 
2010; Basken and Green, 2009). This compound can afford high first-pass tissue extraction 
of radiotracer following intravenous administration (John and Green, 1989; Green, et al., 
2007). Upon tissue uptake, the radiocopper is trapped by intracellular reductive 
decomposition of the copper(II) bis(thiosemicarbazone) chelate, for example by reaction 
with ubiquitous intracellular thiols like glutathione, liberating the 62Cu ion to the 
endogenous copper pool of the cell (Petering, 1980; John and Green, 1990; Shelton, et al., 
1989, 1990; Mathias, et al., 1990; Baerga, Michael, and Green, 1992; Green, et al., 2007). 
This prolonged ‘microsphere-like’ tissue retention of 62Cu, together with its 10-minute 
physical half-life, allows use of extended image acquisition periods for improved counting 
statistics, as well as implementation of whole-body acquisition protocols similar to those 
employed with [18F]-FDG.
Practical clinical use of the 62Cu requires a rapid and robust radiopharmaceutical synthesis 
method for routine on-demand radiopharmaceutical delivery. The present study reports the 
performance of a commercially manufactured 62Zn/62Cu microgenerator system (Lacy, 
Stephens, and Yue, 2006; Stephens, et al., 2008), and a lyophilized H2ETS kit formulated 
for point-of-use [62Cu]Cu-ETS synthesis, in the delivery of [62Cu]Cu-ETS for whole-body 
PET perfusion imaging in patients with advanced renal carcinoma and head and neck 
cancer.
2 Materials and Methods
2.1 Preparation of the generator
All 62Zn/62Cu microgenerators were manufactured by Proportional Technologies, Inc., (PTI, 
Houston, Texas) and shipped to the Melvin and Bren Simon Cancer Center PET/CT at 
Indiana University. The generators were calibrated for 9:00 AM on the day of clinical use. 
The microgenerator houses a 50-µL AGl×8 (200–400 mesh) anion exchange resin connected 
to a pressurized eluent vessel containing 0.2M HCL and 1.8M NaCl elution buffer. The 
tungsten-shielded generator-column is contained within a cylindrical stainless steel outer 
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housing. Upon arrival, the generator unit was removed from the shipping packaging, and 
installed on the elution stand (Figure 2) as described in PTI’s IND documentation and 
Investigator Brochure. While PTI has an electronic control box that can automatically open 
the generator’s elution valve for the standard 30-second elution, for the studies described we 
instead elected to simply manually open and close that single-rotation valve using a 
stopwatch timer to track the elution period.
2.2 Generator elution
An initial 90-second flushing elution was always performed before any patient dose was 
prepared. For this flushing elution, after venting to atmospheric pressure a 5.0 mL empty 
sterile elution vial was placed in the vial shield, positioned underneath the generator, and 
raised into position for elution (Figure 2D). A total volume of approximately 0.75 mL is 
eluted into the vial during this 90-second period. Eluted radioactivity was measured using a 
dose calibrator (Atomlab 100 Medical System, calibration setting of 9.5). After the assay, 
the vial was stored for later measurement of 62Zn breakthrough after complete decay of the 
initial 62Cu.
For subsequent radiopharmaceutical preparations, a standard 30-second elution was 
performed to deliver 62Cu2+ in a volume of 0.25 mL directly into the reconstituted reaction 
vials. If the elapsed time between two consecutive elution was more than one hour, a 30-
second flushing elution was carried out 30–40 minutes before the planned dose delivery, as 
elution yields were observed to drop and become more variable when more than one hour 
elapsed between elutions.
The 62Cu elution efficiency was determined by comparison of the recovered 62Cu 
radioactivity (decay corrected to time-of-elution) and the calculated 62Cu available at time-
of-elution (Finn, et al., 1983; IAEA, 2010). 62Zn breakthrough levels were determined after 
the eluted 62Cu radioactivity had decayed (>20 hours post-elution), measuring the 
residual 62Zn/62Cu radioactivity using a Nal(TI) well counter with a counting window 
centered at 511 keV. The measured count rates were converted to dpm based on the 
measured efficiency of the gamma counter for 511 keV photons in the counting window, 
and decay-corrected to 62Zn breakthrough at time-of-elution.
2.3 [62Cu]Cu-ETS radiopharmaceutical synthesis
The sterile and pyrogen-free supplies and reagents used in the production of [62Cu]Cu-ETS 
were supplied by PTI unless otherwise stated. For each synthesis, a lyophilized vial of 
H2ETS ligand (10-mL vial, 2 µg H2ETS, 20 mg sucrose as excipient) was aseptically 
reconstituted with 3.75 mL 25mM NaOAc sterile solution (pH 6.5). The vial was then mixed 
with gentle swirling until all of the lyophilized cake was dissolved, yielding within seconds 
a clear and colorless solution with no visible particles. Then, the reconstituted ligand vial 
was placed inside the vial shield, and positioned for generator elution.
A volume of approximately 0.25 mL 62Cu2+ in the acidic eluate was delivered directly into 
the ligand vial over a 30-second elution period. The reaction vial was removed from the 
generator stand, and mixed thoroughly (30 seconds) in order to ensure homogeneous mixing 
and completion of the chelation process between the 62Cu2+ and H2ETS ligand. Each 
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preparation of the day was considered a sub-batch, with the first daily sub-batch employed 
solely for a required radiochemical purity assay.
For each patient administration, a new [62Cu]Cu-ETS synthesis was carried out. The 
synthesis was initiated with generator elution approximately 5-minutes before the intended 
injection. Immediately after the synthesis, all 4-mL of injectable solution was directly 
withdrawn from the shielded reaction vial into a shielded 5-mL sterile syringe through a BD 
TwinPak device. Finally, the product was filtered through a sterile 0.22-µm PVDF 
membrane filter (Whatman Puradisc™ 13 mm) into another sterile 5-mL BD syringe (BD, 
Franklin Lakes NJ, USA). Although the radiopharmaceutical synthesis uses sterile and 
pyrogen-free reagents, and the synthesis process was carried out with aseptic technique in a 
closed system, the final terminal filtration was performed as a redundant process for 
ensuring product sterility. (This terminal filtration was not the primary control for product 
sterility.)
Immediately after the filtration process was completed, the radioactivity in the syringe was 
measured using a dose calibrator, the time of assay recorded, and the dosage was delivered 
for patient administration. The time of the patient injection was recorded, followed by 
measurement of residual radioactivity in the injection syringe, and the injected radioactivity 
calculated.
2.4 Radiochemical purity assay
Standard assay: Oasis HLB cartridge method—An Oasis HLB (hydrophilic 
lipophilic balance) cartridge (Waters, USA) was connected to a 3.0 mL receiving syringe 
using a clip assembly, and the entire set-up was mounted onto a mini lab jack. Before use, 
the Oasis HLB column was pre-conditioned with 1.0 mL of methanol (Mallinckrodt 
Chemicals, USA), followed by 2.0 mL NaOAc buffer (25 mM, pH 4.7). The waste was 
collected in a 3.0-mL syringe at the outlet of the cartridge and was discarded, leaving the 
column bed wetted with buffer.
Immediately after the [62Cu]Cu-ETS synthesis, a 0.1 mL sample of the quality control sub-
lot was withdrawn from the vial with a 1.0 mL syringe and diluted with 0.9 mL of NaOAc 
buffer. The sample was mixed thoroughly, and loaded onto the prepared Oasis HLB column. 
The column was eluted by drawing 1.0 mL NaOAc buffer through the column, collecting 
the eluate in a 3.0 mL receiving syringe. The radioactivity of the aqueous HLB column 
eluate, and remaining on the HLB column was measured, and the times of measurements 
were recorded. Total time for the entire procedure was also recorded. [62Cu]Cu-ETS 
radiochemical purity was calculated using the decay-corrected radioactivity measurements 
for the aqueous eluate and the HLB column as follows:
Alternative assay: C18 Sep-Pak® cartridge method—The C18 Sep-Pak® method 
was carried out in tandem with the standard Oasis method. In the Sep-Pak® method, a 
single-use solid phase extraction (SPE) C18 SepPak Light Cartridge (Waters, Milford, MA, 
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USA) was pre-hydrated and pre-conditioned manually with 5.0 mL of absolute ethanol 
followed by 10.0 mL of deionized water. A volume of 0.05 mL [62Cu]Cu-ETS product 
solution was withdrawn from the quality control sub-lot reaction vial, and diluted with 0.95 
mL deionized water. The sample was mixed thoroughly and then loaded into the SPE 
column. The loading eluate was collected into a test tube (“A”). Next, the C18 Sep-Pak® 
Light was eluted with 10.0 mL of water, followed by 10.0 mL of air flush. This aqueous 
eluate was also collected in tube “A”, and contains ionic impurities (e.g. 62Cu2+ 
and 62Zn2+). In order to recover the lipophilic [62Cu]Cu-ETS complex, the Sep-Pak® was 
then eluted with 1.0 mL ethanol, followed by 5.0 mL of air flush. The ethanol fraction was 
collected in tube “B”. The ‘dry’ cartridge was placed in test tube “C”. Finally, the 
radioactivity of samples A, B, and C was determined using a radionuclide dose calibrator, 
and the radiochemical purity of the [62Cu]Cu-ETS was calculated as:
3 Results
3.1 Performance of the 62Zn/62Cu microgenerator
All 42 generators arrived as scheduled, but five were not used to prepare the patient doses 
because of last-minute patient cancellations, or local cyclotron problems that prevented 
delivery of the [15O]-water required by the imaging protocol as a reference tracer for tumor 
perfusion assessment. The average 62Zn at 9:00 AM Eastern Time on the day of clinical use 
was 1.84 ± 0.23 GBq (49.8 ± 6.2 mCi, range: 1.67 to 2.04 GBq or 45 to 55 mCi). These 
results include two generators loaded with relatively low 62Zn activity (24 and 30 mCi), due 
to manufacturing problems. If these two generators are excluded from the calculations, the 
average activity of 62Zn at calibration time was 1.88 ± 0.13 GBq (50.9 ± 3.43 mCi). The 
entire generator set-up process, from receiving the generator shipment to delivery of the first 
patient dose, took approximately 1.5 hours.
3.2 Evaluation of 62Cu yield
The generator elution yield was calculated based on the elutions made in the clinical study 
day (Day 1; 30-second elution period; elapsed time between two successive elutions of <1 
hour). The generators were not used for patient doses on Day 2, due to the reduced level of 
available 62Cu, but remained useful on Day 2 for other radiochemistry studies. The 62Cu 
elution yield of all generators in Day-1 is shown in Figure 3. The results show that all of the 
generators exhibited a high elution yield that ranged from 60% to 100% with an overall 
average of 89.9 ± 12.9%.
We occasionally observed elution yields calculated to exceed 100%. This could reflect the 
calculated available level of 62Cu neglecting in-growth of 62Cu during the 30-second elution 
process itself, as well as 62Cu radioactivity partially remaining (and recovered) from the 
previous elution if the successive elution were carried out at short time intervals. 
Additionally, the loaded 62Zn radioactivity may slightly exceed the amount shown on the 
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package label, reflecting within-limits variations in the accuracy of the dose calibrators 
employed at the manufacturing and clinical sites.
Figure 4 shows the generator elution yields plotted as a function of the time period between 
elutions, with intervals varying from 10 minutes to more than 1.5 hours. The results show 
that within the 10-to-60 minute intervals, the yield was high, consistent, and reproducible, 
averaging 90% (n = 152). However, when the elapsed time from the preceding elution 
exceeded 1 hour, the yield decreased (73.4 ± 24.3%; n = 34) and became more variable.
This variation in elution yield with the period between elutions was never observed on Day 
2, when the radioactivity level on the column was over 4-fold lower than on Day 1. Because 
the observed declines in yield were clearly reversible in subsequent elutions (yield was 
readily recovered by a 30-second flushing elution 30–40 minutes prior to the next elution), 
there does not appear to be channeling damage to the column. Instead, we suspect that the 
altered yield reflects a reversible physical change, such as formation of gas bubbles in the 
column bed, due to the high Day-1 concentration of radioactivity on the column. The high 
elution efficiency observed when controlling the period between elutions assured that even 
at 5:00 pm on Day 1 the generator could deliver levels of 62Cu sufficient for patient studies.
3.3 Evaluation of 62Zn breakthrough
Table 1 summarizes the 62Zn breakthrough levels found in the first elution (90-second 
flushing elution, 0.75 mL), and the average value of breakthrough in the subsequent 30-
second elutions (0.25 mL/elution; n ≥ 3) for a subset of 20 of the generators used. Overall, 
the eluted 62Zn constituted less than 0.001% of the total eluted 62Cu activity. All the 
generators had breakthrough levels that were less than 0.1 µCi of 62Zn, with values ranging 
as low as 0.0001 µCi.
The fractional breakthrough of the 62Zn was determined as the eluted 62Zn relative to the 
total 62Zn activity present on the column at the time-of-elution. The chloride concentration, 
elution flow rate, elution volume, and column resin bed size are all fixed, but one factor that 
could contribute to variations in parent breakthrough is the number of prior elutions 
(reflecting the total cumulative eluent volume passed through the column). Since even for 
strongly absorbed solutes there is always a bound ⇆ free equilibrium, the bound 62Zn 
nuclide could migrate from the top of the generator column to the lower part of the column 
with high elution volumes, potentially increasing 62Zn leakage in later elutions. However, 
examination of the pattern of breakthrough in a subset of eight generators (Figure 5), 
provides no indication of any significant bulk migration of 62Zn through the column bed, 
even at the highest elution volumes one could encounter in clinical generator use.
These studies confirm that the radionuclidic purity of the delivered 62Cu was more than 
99.99% throughout the shelf-life of these generators. The extremely low levels of 62Zn 
contaminant in the 62Cu-radiopharmaceutical product will make a negligible contribution to 
total patient radiation exposure. For example, even a 1.0 µCi 62Zn contaminant in the 62Cu 
product will contribute only a 0.16 mGy (16 mRad) exposure to the liver (the critical organ 
for 62Zn), based on published dosimetry, with a corresponding effective dose equivalent of 
only 0.018 mSv (1.8 mRem) (ICRP, 1988).
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3.4 Performance of the kit-based method for [62Cu]Cu-ETS synthesis
The [62Cu]Cu-ETS synthesis protocol is relatively simple, straightforward, and easy to 
perform. Over a period of three years, using 37 generators, a total of 45 doses of the Cu-ETS 
were successfully prepared for use in PET perfusion imaging at Indiana University Hospital. 
Every batch passed the radiochemical purity test standard (>95%), with an average 
radiochemical purity of 98.1 ± 1.1% (n=40) using standard Oasis-based assay method. 
Equivalent radiochemical purity values were obtained using the alternative C18 Sep-Pak® 
method, where values averaged 97.8 ± 0.9% (n=28). The synthesis process was rapid and 
robust, taking approximately 3.5 minutes to complete, resulting in an average elapsed time 
of 4.5 ± 0.9 minutes (n = 45) from start-of-generator-elution to patient-injection. The mean 
injected dose was 18.2 ± 4.6 mCi (672 ± 172 MBq; n=45).
4 Discussion
Generator-produced positron-emitting radioisotopes provide a practical route to performance 
of PET with short-lived radionuclides, even in the absence of a nearby cyclotron. The results 
of the present study confirm the commercially produced 62Zn/62Cu microgenerator to be a 
reliable source for on-site production of 62Cu-radiopharmaceuticals. The generator set-up is 
easy and rapid, even in a space-limited PET hot lab. The generator module does not require 
a hot cell, as the integrated shielding is sufficient to protect the operator during generator 
elution and radiopharmaceutical synthesis. The elution process efficiently recovers nearly all 
of the available 62Cu from the column in a very small volume (0.25 mL) of dilute HCI 
solution. This small elution volume facilitates in situ adjustment of the final product’s pH 
and isotonicity.
The kit-based [62Cu]Cu-ETS synthesis procedure, from the beginning of the generator 
elution to the patient injection, involves only few simple steps: (1) a 30-second ligand 
reconstitution in the kit vial; (2) a 30-second generator elution of 62Cu; (3) 30 seconds of 
mixing; (4) 0.5 to 1 minutes for the 0.2-µm membrane filtration process; and finally, (5) 
radiopharmaceutical injection. The 62Cu-generator eluate is delivered directly into the kit 
vial, where it is buffered by sodium acetate and allowed to react with the 
bis(thiosemicarbazone) chelating ligand (Figure 1). The resulting 4.0-mL isotonic product 
solution (pH 4.5–5) is suitable for direct intravenous administration. This simple procedure 
minimizes the time needed for radiopharmaceutical synthesis, and thus minimizes pre-
injection radionuclide loss due to decay. We did not encounter a single failure in [62Cu]Cu-
ETS dose delivery over the three-year study period. This simple “elute and mix” synthesis 
protocol can be conveniently implemented in any clinical facility, with the lyophilized kit 
formulation enabling the robust and reliable on-demand production of Cu-labeled 
radiopharmaceuticals.
The sole disadvantage of the 62Zn/62Cu generator is the somewhat short half-life of the 
cyclotron-produced 62Zn parent (9.2 hours), as it limits the generator to a one to two day 
shelf-life. This limitation is somewhat offset by the capability of the generator to produce 
radiopharmaceutical doses at 30–40 minute intervals throughout the day of use. In addition 
to the present example, where we focused only on delivery of [62Cu]Cu-ETS for perfusion 
imaging, the kit-based methodology can also be applied to [62Cu]Cu-PTSM or [62Cu]Cu-
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ETSM for cerebral perfusion imaging, [62Cu]Cu-ATSM for tumor hypoxia imaging, 
and 62Cu-labeling of peptide-chelate conjugates (John and Green, 1989; Mathias, et al., 
1990; Fujibayashi, et al., 1997; Lewis, et al., 1999; Castle, et al., 2003; Vavere and Lewis, 
2007; Mathias, et al., 2013).
The production process for the 62Zn/62Cu microgenerator is fully scalable in response to 
clinical demand. The 62Zn can be readily produced in very large quantities via the 63Cu(p,
2n)62Zn nuclear reaction using a medium energy cyclotron. A GMP-compliant cyclotron 
facility could centrally produce 62Zn/62Cu generators for nationwide distribution relying on 
standard overnight delivery services.
The manufacturer’s Oasis-column method, and the alternative C18 Sep-Pak® method, were 
equally effective as approaches to verifying product radiochemical purity. However, we 
preferred the C18 Sep-Pak® method, due to its speed and simplicity (notably requiring less 
operator care than the Oasis method in conditioning the stationary phase, since one does not 
need to visually monitor the solvent being drawn down to the top of the stationary phase 
bed).
5 Conclusions
The 62Zn/62Cu microgenerator has served as a reliable source for “on-demand” delivery of 
short-lived positron-emitting 62Cu at a clinical site. The generator consistently provided 
high 62Cu elution yields, coupled with extremely low 62Zn breakthrough. The kit-based 
[62Cu]Cu-ETS synthesis method has proven to be convenient, rapid, reliable, and robust. 
Analysis and validation of the performance of [62Cu]Cu-ETS in whole-body tumor 
perfusion imaging is in progress (Fletcher, et al., 2014).
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Highlights
The microgenerator system is a dependable high-yield source of positron-emitting 62Cu.
Synthesis of the [62Cu]Cu-ETS radiopharmaceutical is rapid and reliable.
Kit-based production methods offer the convenience required for clinical PET with 62Cu-
agents.
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Figure 1. 
Synthesis and chemical structure of the [62Cu]Cu-ETS radiopharmaceutical.
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Figure 2. 
The 62Zn/62Cu microgenerator produced by Proportional Technologies, Inc. (Houston). A: 
Generator unit as delivered to the clinical site via overnight shipment. B: Generator and 
disassembled stand and shielding. C: Assembled generator stand and shielded elution vial. 
The fulcrum on the base of the stand allows the shielded vial to be raised into the generator 
housing, whereupon the generator outlet needle punctures the septum of the vial. D: 
Generator with shielded vial positioned for elution. In the background one can also see the 
tungsten shield for the 5-mL syringe used to withdraw the patient dose from the shielded 
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product vial. This syringe shield is designed to securely mate with guide holes in the vial 
shield, thereby controlling the position and depth of needle penetration into the vial septum, 
and allowing nearly quantitative dose withdrawal with limited radiation exposure to the 
hands of the operator.
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Figure 3. 
The elution yields of 62Cu from 42 generators on the day of receipt (overall mean: 89.9 ± 
12.9%; 30-second elution period, elapsed time from prior elution < 1 hour).
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Figure 4. 
The 62Cu elution yield on the day of generator receipt plotted as a function of the elapsed 
time since the preceding elution for 42 generators. The elution yield was observed to 
decline, and become more variable, when the elapsed time between elutions was greater than 
60 minutes.
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Figure 5. 
62Zn breakthrough (62Zn breakthrough/total 62Zn at time-of-elution) from a subset of 
eight 62Zn/62Cu generators studied, each with total cumulative eluted volume of ≥ 2.5 mL 
The fraction of leakage remained < 5× 10−5 for up to a 3.5 mL cumulative elution volume 
(10–12 elutions).
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Table 1
Levels of 62Zn-breakthrough in the initial 90-second (0.75-mL) flushing elution, and subsequent 30-second 
(0.25-mL) elutions. Values shown are decay-corrected to time-of-elution.
Generator I.D. 62Zn Breakthrough in Initial
90-sec Elution
(µCi)
62Zn Breakthrough
in Subseque 30-sec
Elutions
(µCi)
(Mean ± SD; n ≥ 3)
Z260 0.01 0.0006 ± 0.0004
Z261 0.002 0.003 ± 0.005
Z262 0.01 0.009 ± 0.0007
Z263 0.0002 0.0001 ± 0.00006
Z264 0.0006 0.00025 ± 0.0002
Z266 0.0075 0.006 ± 0.0005
Z267 0.006 0.01 ± 0.006
Z268 0.003 0.002 ± 0.0009
Z269 0.0039 0.03 ± 0.02
Z270 0.0002 0.0001 ± 0.00007
Z271 0.01 0.04 ± 0.03
Z273 0.09 0.05 ± 0.006
Z274 0.0076 0.012 ± 0.008
Z275 0.004 0.034 ± 0.03
Z276 0.0002 0.0006 ± 0.0005
Z280 0 0
Z281 0.003 0.001 ± 0.001
Z283 0.002 0.002 ± 0.001
Z286 0 0
Z393 0 0
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